What Administration Sites Need to Know

Monoclonal antibodies (or mAbs) are a critical tool in fighting the COVID-19 pandemic, and the U.S. Department of Health and Human Services (HHS) is committed to fair and equitable access to these important products.  A surge in the Delta variant coupled with low vaccination rates in certain areas of the country contributed to an increase in COVID-19 over the July-August timeframe.

As a result, the HHS Office of the Assistant Secretary for Preparedness and Response (HHS/ASPR) implemented a State and Territorial-Coordinated Distribution System for mAbs on Sep 13, 2021, similar to one that was in place from November 2020 to February 2021.  Currently, REGEN-COV and bamlanivimab/etesevimab are being distributed through this state/territory coordinated distribution system. 

Step 1 HHS/ASPR announces distribution quantities each Tuesday	Step 2 State/territorial health departments allocate product administration sites	Step 3 Administration sites dispense mAbs to eligible patients	Step 4 Administration sites report on product utilization and stock on hand on Wednesdays by 11:59 PM ET
View Distribution Tables >>	About Receiving Product >>	Patient Eligibility >>	Reporting Requirements >>

Questions? If you have questions about the new state/territory coordinated distribution system, check out our frequently asked questions section.                 View the FAQs >>